Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615270 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
A Early Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT07615270: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT07615270 is a Early Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07615270, a Early Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
Primary Outcome
Amyloid target lesion size will be assessed using RECIST v1.1 criteria. Measurements will be obtained at baseline and at Weeks 12, 24, 36, 48, and 72. The outcome will evaluate change from baseline in target lesion size.
Interventions
- DRUG Anselamimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
What is known before NCT07615270 opens enrollment
NCT07615270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Anselamimab is the first listed.
NCT07615270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07615270 about?
NCT07615270 is a clinical study titled "A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement". This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
What is the current status of trial NCT07615270?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07615270?
The interventions under investigation include: Anselamimab (DRUG).
Who is sponsoring clinical trial NCT07615270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07615270's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia